Clinical trial · Interventional
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
NCT02905916CI-TRIAL-00023927unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Tumour | Bone Neoplasm | ALIAS | 0.90 |
| Gynecological Tumors | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Mammary Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PEG-rhG-CSF | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PEG-rhG-CSF
- interventionNames
- Drug: PEG-rhG-CSF
Primary outcomes (1)
- measure
- Incidence of febrile neutropenia (FN)
- timeFrame
- 30days after PEG-rhG-CSF administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria:
1. Patients with age between 18 and 70 years.
2. Breast cancer, lymphoma, bone tumor or Gynecologic tumor patients.
3. With multi-cycle chemotherapy.
4. With III/IV degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.FN risk of the chemotherapy regimens is ≥20%，or 10%≤FN risk\<20% and has high risk factors associated with FN.
5. KPS score≥ 70.
6. Expected to survive more than 3 months.
7. No hematologic system disease and ANC≥1.5×10E9/L, PKT≥80×10E9/L, Hb≥ 75g/L, WBC≥3×10E9/L, and no bleeding tendency.
8. Written informed consent are acquired. -
Exclusion Criteria:
1. With infection or systemic antibiotic therapy 72h before chemotherapy.
2. With any abnormal hematopoietic function.
3. Received transplantation within 3 months.
4. Suffered from other malignant tumor or brain metastases.
5. TBIL, ALT,AST \> 2.5×ULN; if it were caused by liver metastases, TBIL, ALT,AST \>5×ULN.
6. Cr \>1.5 ×ULN.
7. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.
8. Mental or nervous system disorders.
9. Refused to accept contraceptive measures.
10. Other situations that investigators consider as contra-indication for this study.
\-References
Publications (0)
Data not yet available
No reference posted for this study.